Ozempic Price in India 2026 — and the ₹5,999 Alternative Your Doctor Can Prescribe Today

If you searched Ozempic price India any time before this year, the number that came back was frightening: ₹18,000 to ₹22,000 a month, and that was if you could find it. That figure was real — but it described a grey market, not a pharmacy shelf. Ozempic wasn't officially sold in India then. People imported pens, paid import margins on an already premium drug, and accepted that supply could vanish for weeks.

That era is over. And the new numbers change the entire calculation for anyone considering a GLP-1 for weight loss.

What Ozempic actually costs in India in 2026

Ozempic launched officially in India in December 2025. After Novo Nordisk's April 2026 price cut, the starting 0.25 mg dose costs around ₹5,660 a month. But almost nobody stays on the starting dose — it exists only to let your body adjust. As you titrate up to a maintenance dose, the monthly cost climbs to roughly ₹8,000–₹16,000 depending on strength.

So the honest answer to “what does Ozempic cost in India” is: less than the scary import numbers you remember, but still ₹1–1.6 lakh a year for the drug alone at a real maintenance dose — before a single consultation, blood test, or follow-up.

Why it kept going out of stock

The stockouts weren't a glitch — they were structural. Global demand outstripped manufacturing for years, and India, a smaller and lower-priced market, sat near the back of the supply queue. When you buy an imported pen through informal channels, a shipment delay in another country becomes your missed dose here.

Even now that Ozempic is officially distributed, two frictions remain: brand supply can still tighten when global demand spikes, and the cost of escalating to a full dose makes long-term adherence expensive. For a treatment that only works while you take it, an erratic or unaffordable supply isn't a minor inconvenience — it's a treatment failure waiting to happen.

Semaglutide is a molecule, not a brand

Here is the single most useful thing to understand before you spend a rupee. Semaglutide is the active molecule — a GLP-1 receptor agonist that slows how fast your stomach empties, blunts appetite, and quiets the food-noise that drives overeating. Novo Nordisk discovered it and sells it under two brand names: Ozempic (for diabetes) and Wegovy (for weight management). Same molecule, different doses, different boxes, very different prices.

You are not paying ₹16,000 a month for a superior chemical. You're paying for a brand and a patent. The drug working inside your body is semaglutide either way.

March 20, 2026: the patent expired

On 20 March 2026, Novo Nordisk's semaglutide patent expired in India. Within days, more than 40 Indian pharmaceutical companies — Sun Pharma, Dr. Reddy's, Cipla, Zydus, Natco, Glenmark, Lupin and others — launched their own DCGI-approved versions of the exact same molecule.

The prices tell the story. Generic semaglutide now starts at around ₹1,290 a month. These aren't knock-offs in any clinical sense; they are the identical molecule, made to regulatory standard and cleared by India's drug regulator. India is one of the first major markets where this competition is legal — in the US and Europe, the patents run into the 2030s.

So what should you actually pay?

Go the branded route and you're looking at ₹8,000–₹16,000 a month for the drug at a maintenance dose, plus finding a doctor to prescribe and monitor it, plus your own baseline and follow-up bloodwork. Done properly, that's well past ₹1.5 lakh a year.

The generic molecule costs a fraction of that. But buying a ₹1,290 vial off a counter and self-injecting is exactly the wrong lesson. Semaglutide is safe and effective when it's dosed, titrated, and monitored correctly — and risky to treat casually. The molecule got cheap; the medical supervision is what you should still pay for.

The ALTRcare programme: same molecule, supervised, ₹5,999

This is the gap our programme is built for. ALTRcare's monthly programme is ₹5,999, all-in — generic semaglutide (the same molecule as Ozempic and Wegovy), a doctor-led prescription and titration plan, side-effect management, and ongoing monitoring. No brand premium, no grey-market guesswork, no leaving the medical part to a video.

“The branded-versus-generic confusion costs Indian patients real money and real time. Ozempic and Wegovy are excellent drugs — but the molecule inside them is semaglutide, and that molecule is now legal, regulated, and affordable in India. The barrier was never the science; it was a patent and a price. What patients actually need isn't a brand name. It's the right dose, titrated carefully, with someone watching their bloodwork.”

A few honest caveats

Semaglutide is a prescription medicine, not a lifestyle supplement. It isn't right for everyone, it requires baseline bloodwork before you start, and nausea or reduced appetite are common in the first few weeks. Serious effects are rare but real, which is why starting low, going slow, and being monitored matters. A doctor decides whether you're a candidate — not a marketing page.